
Coherus BioSciences CHRS
$ 1.42
6.77%
Quarterly report 2025-Q3
added 11-06-2025
Coherus BioSciences Depreciation & Amortization 2011-2025 | CHRS
Annual Depreciation & Amortization Coherus BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.2 M | 3.6 M | 3.5 M | 2.89 M | 3.26 M | 3.24 M | 3.4 M | 3 M | 1.87 M | 674 K | 404 K | 221 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.6 M | 221 K | 2.44 M |
Quarterly Depreciation & Amortization Coherus BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 300 K | 300 K | 400 K | - | 400 K | 500 K | 600 K | - | 800 K | 800 K | 900 K | - | 900 K | 900 K | 767 K | - | 900 K | 900 K | 849 K | - | 700 K | 700 K | 607 K | - | 800 K | 700 K | 691 K | - | 800 K | 902 K | 922 K | - | 800 K | 838 K | 865 K | - | 800 K | 729 K | 717 K | - | 636 K | 400 K | 232 K | - | 192 K | 131 K | 116 K | - | 101 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 922 K | 101 K | 638 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
AbbVie
ABBV
|
764 M | $ 223.01 | -0.99 % | $ 395 B | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
1.4 M | $ 4.68 | 1.85 % | $ 777 M | ||
|
Aclaris Therapeutics
ACRS
|
807 K | $ 3.38 | 3.21 % | $ 261 M | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 1.33 | -1.48 % | $ 7.25 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
28.2 M | $ 25.76 | 0.19 % | $ 1.25 B | ||
|
Anika Therapeutics
ANIK
|
6.43 M | $ 9.53 | -1.19 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
172 M | - | 0.49 % | $ 251 B | ||
|
Biogen
BIIB
|
673 M | $ 173.03 | -2.55 % | $ 25.2 B | ||
|
BioVie
BIVI
|
229 K | $ 1.54 | -2.53 % | $ 2.28 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.33 | 2.3 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
3.87 M | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
165 K | - | 0.59 % | $ 63 K | ||
|
Catalyst Biosciences
CBIO
|
1.07 M | $ 15.32 | 5.73 % | $ 1.01 B | ||
|
ChromaDex Corporation
CDXC
|
663 K | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
48.4 M | $ 586.28 | 3.15 % | $ 44.4 B | ||
|
Cerus Corporation
CERS
|
1.86 M | $ 2.14 | 13.23 % | $ 395 M | ||
|
Caladrius Biosciences
CLBS
|
174 K | - | -16.75 % | $ 25.8 M | ||
|
Celldex Therapeutics
CLDX
|
3.18 M | $ 28.33 | 0.5 % | $ 1.82 M | ||
|
Cellectar Biosciences
CLRB
|
192 K | $ 3.81 | -5.35 % | $ 46.6 M | ||
|
Clovis Oncology
CLVS
|
8.5 M | - | -7.23 % | $ 13 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 0.29 | -5.01 % | $ 631 M | ||
|
Cortexyme
CRTX
|
322 K | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
66 K | $ 12.91 | 0.78 % | $ 531 M | ||
|
Cytokinetics, Incorporated
CYTK
|
9.53 M | $ 60.38 | 0.11 % | $ 6.76 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
24.9 M | $ 11.55 | 8.86 % | $ 747 M | ||
|
Dynavax Technologies Corporation
DVAX
|
4.63 M | $ 10.89 | -0.09 % | $ 1.42 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
77 K | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M |